section name header

Pronunciation ⬇

ta-FAM-id-is

Classifications ⬆ ⬇

Therapeutic Classification: none assigned

Pharmacologic Classification: temporary class

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Acts as a transthyretin (TTR) stabilizer by selectively binding to TTR at the thyroxine binding sites and stabilizing the tetramer of the TTR transport protein by slowing its dissociation into monomers, which is the rate-limiting step in the amyloidogenic process.
Therapeutic effects:
  • Reduction in mortality and cardiovascular hospitalizations.

Pharmacokinetics ⬆ ⬇

Absorption: Unknown.

Distribution: Well distributed to tissues.

Protein Binding: >99%.

Metabolism/Excretion: Metabolic pathway not fully known (may undergo glucuronidation). 59% excreted in feces (primarily as unchanged drug); 22% excreted in urine (primarily as metabolites).

Half-Life: 49 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POUnknown4 hr24 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

No adverse reactions reported in prescribing information.

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Vyndaqel

Vyndamax

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Vyndamax, Vyndaqel

Code ⬆

NDC Code